New Risk • Jul 05
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: €172k (US$186k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (6,663% average daily change). Negative equity (-€32m). Earnings have declined by 7.9% per year over the past 5 years. Revenue is less than US$1m (€172k revenue, or US$186k). Market cap is less than US$10m (€869 market cap, or US$940). 공시 • May 09
Pharnext SA, Annual General Meeting, Jun 10, 2024 Pharnext SA, Annual General Meeting, Jun 10, 2024. Location: 14 rue de la republique, suresnes France Board Change • Feb 15
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Member of the Supervisory Board Guy-Charles de la Horie was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Feb 01
Pharnext SA announced that it has received €41.188458 million in funding Pharnext SA announces private placement of 30,783,601,087 shares for an issue price of €0.001338 per shares for gross proceeds of €41,188,458 on January 31, 2024. Board Change • Jan 22
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Member of the Supervisory Board Guy-Charles de la Horie was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Jan 16
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€24m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€24m free cash flow). Share price has been highly volatile over the past 3 months (405% average daily change). Negative equity (-€31m). Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (€156 market cap, or US$170). Minor Risk Revenue is less than US$5m (€1.8m revenue, or US$2.0m). New Risk • Dec 27
New major risk - Revenue and earnings growth Earnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (367% average daily change). Negative equity (-€31m). Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (€156 market cap, or US$173). Minor Risk Revenue is less than US$5m (€1.8m revenue, or US$2.0m). 공시 • Jan 04
Pharnext Strengthens Its Senior Leadership Team with the Appointment of Scott Johnson as VP, Head of Quality Pharnext SA announces the appointment of Scott Johnson as VP, Head of Quality. This appointment further strengthens the Company's Senior Leadership Team. Scott has more than 15 years of experience in quality management and compliance within the healthcare sector. He joins from Oyster Point Pharma, where he was Head of Quality Assurance. There, he established and implemented a comprehensive quality management system and oversaw all quality-related functions during the submission of an NDA application and successful launch of Oyster Point's first commercial product. Prior to Oyster, Scott served as Director, Quality Assurance at Lupin Pharmaceuticals where he had overall responsibility for quality and compliance. He has also held roles at Johnson & Johnson and Warner Chilcott. Scott has a BA in Organizational Management from the Eastern University, St. David's, PA and previously served in the United States Navy. At Pharnext, Scott will continue to develop and maintain the Company's Quality strategy and ensure its operational execution. He will oversee the Quality activities in the areas of Manufacturing (Good Manufacturing Practices), Laboratory (Good Laboratory Practices) and Clinical (Good Clinical Practices) to ensure compliance with regulatory requirements. Scott will also be responsible for promoting a quality mindset across the Company and working with cross-departmental leadership to ensure the delivery of high-quality products and services. Board Change • Nov 16
No independent directors There are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 8 non-independent directors. Director Hugo Brugiere was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Reported Earnings • Oct 18
First half 2022 earnings released First half 2022 results: Net loss: €19.1m (loss widened 41% from 1H 2021). Revenue is forecast to stay flat during the next 2 years compared to a 17% growth forecast for the Biotechs industry in Germany. Board Change • Apr 27
Less than half of directors are independent There are 7 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 10 non-independent directors. Independent Non-Executive Director Piers Morgan was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Oct 16
First half 2021 earnings released First half 2021 results: Net loss: €13.6m (loss widened 49% from 1H 2020). Reported Earnings • Apr 30
Full year 2020 earnings released Full year 2020 results: Net loss: €21.6m (loss narrowed 7.5% from FY 2019). Products in clinical trials Phase II: 1 Phase III: 1 